Johnson & Johnson (JNJ)vsThe Joint Corp (JYNT)
JNJ
Johnson & Johnson
$267.59
-1.61%
HEALTHCARE · Cap: $648.67B
JYNT
The Joint Corp
$7.75
-4.32%
HEALTHCARE · Cap: $114.56M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 167157% more annual revenue ($97.93B vs $58.55M). JNJ leads profitability with a 21.5% profit margin vs 6.5%. JNJ appears more attractively valued with a PEG of 2.82. JNJ earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy59
out of 100
Grade: C
JYNT
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-89.2%
Fair Value
$141.39
Current Price
$267.59
$126.20 premium
Intrinsic value data unavailable for JYNT.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 29.2%
Generating 3.4B in free cash flow
Earnings expanding 653.0% YoY
Every $100 of equity generates 21 in profit
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Earnings declined 0.9%
Smaller company, higher risk/reward
6.5% margin — thin
Operating margin of 3.3%
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 29.2%.
Bull Case : JYNT
The strongest argument for JYNT centers on EPS Growth, Return on Equity, Debt/Equity. Revenue growth of 14.4% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Bear Case : JYNT
The primary concerns for JYNT are Market Cap, Profit Margin, Operating Margin. A P/E of 57.9x leaves little room for execution misses.
Key Dynamics to Monitor
JNJ profiles as a mature stock while JYNT is a value play — different risk/reward profiles.
JYNT carries more volatility with a beta of 1.06 — expect wider price swings.
JYNT is growing revenue faster at 14.4% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 49/100), backed by strong 21.5% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →The Joint Corp
HEALTHCARE · MEDICAL CARE FACILITIES · USA
The Joint Corp. The company is headquartered in Scottsdale, Arizona.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?